Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

PDF Research Advocates Highlight Unmet Needs in Parkinson’s at FDA Meeting

The Parkinson’s Disease Foundation (PDF) is pleased to report that five of its Research Advocates represented the community at last week’s Food and Drug Administration’s (FDA) Patient-Focused Drug Development meeting on Parkinson’s Disease in Silver Spring, MD.

The meeting was the first of its kind in the Parkinson’s community, providing the opportunity for people living with PD and care partners to share insights about life with the disease and those aspects that need more effective treatments.

PDF Research Advocates, along with other community representatives, helped to highlight symptoms and side effects for which there are few effective treatments. For example, Research Advocates focused on disabling nonmotor symptoms, such as pain and cognitive decline and secondary movement symptoms and complications such as dyskinesia and freezing. They also spoke about the need for medications that can provide a steadier therapeutic effect throughout the day.

The PDF Research Advocates who represented the community were:

  • Steve DeWitte, New Preston, CT, person living with PD
  • Todd Hebb, Towson, MD, person living with PD
  • Becky Houde, J.D., Waltham, MA, person living with PD
  • Rosa Kim, West Dundee, IL, former care partner to person with PD
  • Kevin Kwok, Pharm.D., San Francisco, CA, person living with PD

“After advocating for patient engagement in the Parkinson’s community for more than a decade, PDF applauds the FDA for hosting this meeting to gather the perspectives of people living with Parkinson’s disease. We thank our team of Research Advocates for helping to highlight unmet needs in Parkinson’s disease and advocate for more effective treatments,” said Veronica Todaro, M.P.H., Vice President, National Programs at PDF.

She later added in an interview with The Pink Sheet, “The meeting shines the light on the need to engage the people living [with] the disease early and often in the development of research priorities and therapies.”

Do you want to join PDF Research Advocates in sharing insights into life with Parkinson's? PDF, in collaboration with the Parkinson’s Action Network invites you to take the anonymous survey below about life with PD by Friday, October 30. Results will be shared with the FDA to help guide its work.

Tuesday, September 29, 2015
Parkinson's Foundation Study Finds Gender Disparities in Caregiving, with Women at a Disadvantage
Monday, December 4, 2017

Largest Clinical Study Tracking Parkinson’s Patients Over Time Shows Women with Parkinson’s Have Fewer Caregiving Resources than Men with Parkinson’s

Parkinson’s Foundation Invests $60,000 to Develop Innovative Models of Patient Engagement
Wednesday, November 29, 2017

Six Awards Foster Patient-Driven Parkinson’s Research

Jesse Jackson Diagnosed with Parkinson's Disease
Friday, November 17, 2017

Rev. Jesse Jackson’s announcement today that he has been living with Parkinson’s Disease since 2015 further proves that receiving a diagnosis of Parkinson's is not a death sentence. There are many ways that people living with Parkinson's can control the symptoms of the disease with exercise and physical therapy to help maintain mobility and balance.

Update on Tozadenant Trial for Parkinson’s
Thursday, November 16, 2017

On 11/20/17, Acorda Therapeutics, Inc. announced that it is discontinuing the tozadenant clinical trial.  They concluded that they could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety.

Parkinson’s Foundation Adds Marcia Mondavi Borger to Board of Directors
Tuesday, November 14, 2017

NEW YORK & MIAMI — The Parkinson’s Foundation today announced the election of Marcia Mondavi Borger to its Board of Directors.

Parkinson’s Foundation and Melvin Yahr International Parkinson’s Disease Foundation Announce Merger
Thursday, October 26, 2017

Parkinson’s Foundation Establishes ‘Dr. Melvin Yahr Research Award’ to Fund Neurology Fellows, Promote Leadership Diversity in Parkinson’s Research

Parkinson’s Foundation Welcomes Two New Board Members
Tuesday, October 24, 2017

Peter Goldman and Joshua Raskin Join Board of Directors

NEW YORK & MIAMI — The Parkinson’s Foundation today announced the election of Chicago entrepreneur Peter Goldman and New York financial analyst Joshua Raskin to its Board of Directors.

Parkinson's Foundation Unveils New Brand and Website
Thursday, October 19, 2017

NEW YORK and MIAMI /PRNewswire-USNewswire/ — The Parkinson's Foundation today announced the launch of its new brand and website following the recent merger of two legacy organizations – National Parkinson Foundation and Parkinson's Disease Foundation – as part of its mission to

FDA Approves Extended-Release Amantadine (GOCOVRI™) for Treatment of Dyskinesia
Friday, August 25, 2017

Statement from the Parkinson's Foundation Medical Director, Michael Okun, MD

Parkinson’s Foundation Announces $1.2 Million Investment to Advance Careers, Support Innovation of Early Career Parkinson’s Scientists
Tuesday, August 8, 2017

NEW YORK & MIAMI The Parkinson's Foundation is pleased to announce a $1.2 million investment in 27 career development and fellowship grants to support the work of promising early career scientists in the field of Parkinson's.

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.